Firms anticipate long-term markets for prevention and treatment
Why do some medicines stop working, and can we avoid it for Covid-19 antivirals?
Promising results from Pfizer trial, while UK approves Merck & Co’s molnupiravir
Merck & Co and Ridgeback’s molnupiravir reduces risk of hospitalisation and death, and may work against other coronaviruses
Small molecules appear to be lagging behind development of vaccine and antibody treatments
© Royal Society of Chemistry Registered charity number: 207890
Site powered by Webvision Cloud